EHA 2019 Conference Review

In this review:

Iberdomide + dexamethasone in relapsed/refractory MM
Bortezomib and dexamethasone ±venetoclax in relapsed/ refractory MM
KCRD induction for newly diagnosed MM
Venetoclax + ibrutinib for relapsed/refractory CLL
AMG 420 immunotherapy in relapsed/refractory MM
VTD ±daratumumab in transplanteligible newly diagnosed MM
Fixed-duration venetoclax + obinutuzumab in previously untreated CLL
Polatuzumab/obinutuzumab/ lenalidomide in relapsed/ refractory follicular lymphoma
Subcutaneous vs. intravenous daratumumab in relapsed/ refractory MM
Pomalidomide/dexamethasone ±isatuximab in relapsed/ refractory MM

Please login below to download this issue (PDF)